Home - SelectION, Inc.

with superior selectivity and specificity

Therapeutic peptides

toxins of venomous animals

Derived from evolutionary tuned

target ion channels

which selectively

Peptide drugs

for autoimmune patients

Improving quality of life

Targeting Ion Channels

MORE

Our Goal

To improve quality of life for patients by developing best-in-class ion channel blockers.

A highly efficient screening and development platform to identify and optimize the most targeted peptides for our drug development.

News

selectION Secures $5M Promissory Note

September 16, 2020

si-544, a Kv1.3 blocker with class leading selectivity and excellent preclinical safety profile, scheduled to advance towards clinical development in…

Meet selectION Inc. at Biocom’s 10th Annual Global Life Science Partnering Conference in San Diego on February 25th to 27th, 2020

January 9, 2020

SAN DIEGO, January 9, 2020 – Meet Antonius Schuh, Ph.D. (CEO) and Andreas Klostermann, Ph.D. (CSO) for an update on…

with superior selectivity and specificity

Therapeutic peptides

Our Goal

To improve quality of life for patients by developing best-in-class ion channel blockers.

Our Technology

A highly efficient screening and development platform to identify and optimize the most targeted peptides for our drug development.

News & Events

selectION Secures $5M Promissory Note

Meet selectION Inc. at Biocom’s 10th Annual Global Life Science Partnering Conference in San Diego on February 25th to 27th, 2020

About

Recent News

Contact